{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T06:21:25Z","timestamp":1791354085823,"version":"4.3.1"},"reference-count":56,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T00:00:00Z","timestamp":1723593600000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["TO10-13"],"award-info":[{"award-number":["TO10-13"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,2]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Membranous nephropathy (MN) is an antibody-mediated autoimmune disease and the most common cause of nephrotic syndrome in adults. The discovery of phospholipase A2 receptor 1 (PLA2R1) as the first target antigen in patients with MN 15\u00a0years ago has led to a paradigm shift in the pathobiological understanding of this disease. Autoantibodies against PLA2R1 as well as thrombospondin type-1 domain-containing 7A, the second identified antigen in adults, were shown to be disease-causing and act through local activation of the complement system, primarily via the classical and lectin pathways. These findings indicate that both plasma cells, the main source of antibodies and autoantibodies, as well as the complement system, the main pathogenic effector mechanism in MN, are rational and pathogenesis-based treatment targets in MN. This review summarizes pathomechanistic and clinical evidence for and against plasma cell\u2013 and complement-targeted treatments in MN.<\/jats:p>","DOI":"10.1093\/ckj\/sfae243","type":"journal-article","created":{"date-parts":[[2024,8,12]],"date-time":"2024-08-12T11:17:06Z","timestamp":1723461426000},"source":"Crossref","is-referenced-by-count":14,"title":["Therapeutic targets in membranous nephropathy: plasma cells and complement"],"prefix":"10.1093","volume":"17","author":[{"given":"Nicola M","family":"Tomas","sequence":"first","affiliation":[{"name":"III. Department of Medicine, University Medical Center Hamburg-Eppendorf , Hamburg , Germany"},{"name":"Hamburg Center for Kidney Health, University Medical Center Hamburg-Eppendorf , Hamburg , Germany"},{"name":"Hamburg Center for Translational Immunology, University Medical Center Hamburg-Eppendorf , Hamburg , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,8,13]]},"reference":[{"key":"2024090510032153500_bib1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa0810457","article-title":"M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy","volume":"361","author":"Beck","year":"2009","journal-title":"N Engl J Med"},{"key":"2024090510032153500_bib2","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1056\/NEJMoa1409354","article-title":"Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy","volume":"371","author":"Tomas","year":"2014","journal-title":"N Engl J Med"},{"key":"2024090510032153500_bib3","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1038\/s41581-022-00564-1","article-title":"Membranous nephropathy: new pathogenic mechanisms and their clinical implications","volume":"18","author":"Hoxha","year":"2022","journal-title":"Nat Rev Nephrol"},{"key":"2024090510032153500_bib4","doi-asserted-by":"crossref","first-page":"800242","DOI":"10.3389\/fimmu.2021.800242","article-title":"How times have changed! A cornucopia of antigens for membranous nephropathy","volume":"12","author":"Caza","year":"2021","journal-title":"Front Immunol"},{"key":"2024090510032153500_bib5","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.kint.2023.06.032","article-title":"Mayo Clinic consensus report on membranous nephropathy: proposal for a novel classification","volume":"104","author":"Sethi","year":"2023","journal-title":"Kidney Int"},{"key":"2024090510032153500_bib6","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1681\/ASN.2013040430","article-title":"Phospholipase A2 receptor autoantibodies and clinical outcome in patients with primary membranous nephropathy","volume":"25","author":"Hoxha","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"2024090510032153500_bib7","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1681\/ASN.2016010050","article-title":"An indirect immunofluorescence method facilitates detection of thrombospondin type 1 domain-containing 7A-specific antibodies in membranous nephropathy","volume":"28","author":"Hoxha","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"2024090510032153500_bib8","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa1814427","article-title":"Rituximab or cyclosporine in the treatment of membranous nephropathy","volume":"381","author":"Fervenza","year":"2019","journal-title":"N Engl J Med"},{"key":"2024090510032153500_bib9","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1093\/ckj\/sfy005","article-title":"Antiphospholipase 2 receptor antibody levels to predict complete spontaneous remission in primary membranous nephropathy","volume":"12","author":"Rodas","year":"2019","journal-title":"Clin Kidney J"},{"key":"2024090510032153500_bib10","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1093\/ckj\/sfab116","article-title":"Monitoring anti-PLA2R antibody titres to predict the likelihood of spontaneous remission of membranous nephropathy","volume":"14","author":"Jatem-Escalante","year":"2021","journal-title":"Clin Kidney J"},{"key":"2024090510032153500_bib11","doi-asserted-by":"crossref","first-page":"217","DOI":"10.34067\/KID.0005112022","article-title":"Prediagnostic appearance of thrombospondin type-1 domain 7A autoantibodies in membranous nephropathy","volume":"4","author":"Burbelo","year":"2023","journal-title":"Kidney360"},{"key":"2024090510032153500_bib12","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1681\/ASN.0000000000000068","article-title":"Pathogenicity of human anti-PLA2R1 antibodies in minipigs: a pilot study","volume":"34","author":"Reinhard","year":"2023","journal-title":"J Am Soc Nephrol"},{"key":"2024090510032153500_bib13","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1172\/JCI85265","article-title":"Autoantibodies against thrombospondin type 1 domain-containing 7A induce membranous nephropathy","volume":"126","author":"Tomas","year":"2016","journal-title":"J Clin Invest"},{"key":"2024090510032153500_bib14","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1681\/ASN.2010111125","article-title":"Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy","volume":"22","author":"Beck","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"2024090510032153500_bib15","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1053\/sarh.2003.49994","article-title":"A systematic analysis of sequences of human antiphospholipid and anti-beta2-glycoprotein I antibodies: the importance of somatic mutations and certain sequence motifs","volume":"32","author":"Giles","year":"2003","journal-title":"Semin Arthritis Rheum"},{"key":"2024090510032153500_bib16","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1056\/NEJMoa1009742","article-title":"Risk HLA-DQA1 and PLA2R1 alleles in idiopathic membranous nephropathy","volume":"364","author":"Stanescu","year":"2011","journal-title":"N Engl J Med"},{"key":"2024090510032153500_bib17","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMc1511702","article-title":"A mechanism for cancer-associated membranous nephropathy","volume":"374","author":"Hoxha","year":"2016","journal-title":"N Engl J Med"},{"key":"2024090510032153500_bib18","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1681\/ASN.2016010093","article-title":"Long-term exposure to air pollution and increased risk of membranous nephropathy in China","volume":"27","author":"Xu","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"2024090510032153500_bib19","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.2215\/CJN.02930322","article-title":"Toxic occupational exposures and membranous nephropathy","volume":"17","author":"Cremoni","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"key":"2024090510032153500_bib20","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1016\/S0140-6736(22)02039-6","article-title":"Bacterial infection possibly causing autoimmunity: Tropheryma whipplei and membranous nephropathy","volume":"400","author":"Wiech","year":"2022","journal-title":"Lancet"},{"key":"2024090510032153500_bib21","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1681\/ASN.2014050502","article-title":"Identification of a major epitope recognized by PLA2R autoantibodies in primary membranous nephropathy","volume":"26","author":"Fresquet","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"2024090510032153500_bib22","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1681\/ASN.2016040449","article-title":"Rituximab for severe membranous nephropathy: a 6-month trial with extended follow-up","volume":"28","author":"Dahan","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"2024090510032153500_bib23","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.kint.2020.10.014","article-title":"The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy","volume":"99","author":"Fern\u00e1ndez-Ju\u00e1rez","year":"2021","journal-title":"Kidney Int"},{"key":"2024090510032153500_bib24","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1681\/ASN.2020071091","article-title":"Rituximab or cyclophosphamide in the treatment of membranous nephropathy: the RI-CYCLO randomized trial","volume":"32","author":"Scolari","year":"2021","journal-title":"J Am Soc Nephrol"},{"issue":"4 Suppl","key":"2024090510032153500_bib25","first-page":"S1","article-title":"KDIGO 2021 clinical practice guideline for the management of glomerular diseases","volume":"100","author":"Kidney Disease: Improving Global Outcomes Glomerular Diseases Work Group","year":"2021","journal-title":"Kidney Int"},{"key":"2024090510032153500_bib26","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/bjh.15232","article-title":"A tale of two antibodies: obinutuzumab versus rituximab","volume":"182","author":"Freeman","year":"2018","journal-title":"Br J Haematol"},{"key":"2024090510032153500_bib27","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.ekir.2023.01.035","article-title":"Obinutuzumab in refractory phospholipase A2 receptor-associated membranous nephropathy with severe CKD","volume":"8","author":"Naik","year":"2023","journal-title":"Kidney Int Rep"},{"key":"2024090510032153500_bib28","doi-asserted-by":"crossref","DOI":"10.1111\/nep.14331","article-title":"Obinutuzumab in untreated primary membranous nephropathy: an observational case series","author":"Hao","year":"2024","journal-title":"Nephrology (Carlton)"},{"key":"2024090510032153500_bib29","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s40620-013-0028-x","article-title":"Bortezomib therapy for nephrotic syndrome due to idiopathic membranous nephropathy","volume":"27","author":"Hartono","year":"2014","journal-title":"J Nephrol"},{"key":"2024090510032153500_bib30","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.kint.2021.04.011","article-title":"Bortezomib plus dexamethasone for rituximab-resistant PLA2R+ membranous nephropathy","volume":"100","author":"Salhi","year":"2021","journal-title":"Kidney Int"},{"key":"2024090510032153500_bib31","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1159\/000515087","article-title":"Bortezomib treatment for refractory PLA2R-positive membranous nephropathy","volume":"1","author":"Geara","year":"2021","journal-title":"Glomerular Dis"},{"key":"2024090510032153500_bib32","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.kint.2021.12.019","article-title":"Daratumumab for multidrug-resistant phospholipase-A2 receptor-related membranous nephropathy","volume":"101","author":"Vink","year":"2022","journal-title":"Kidney Int"},{"key":"2024090510032153500_bib33","doi-asserted-by":"crossref","first-page":"520","DOI":"10.3389\/fimmu.2014.00520","article-title":"IgG subclasses and allotypes: from structure to effector functions","volume":"5","author":"Vidarsson","year":"2014","journal-title":"Front Immunol"},{"key":"2024090510032153500_bib34","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1093\/ajcp\/83.4.415","article-title":"Immunohistopathologic evaluation of C1q in 800 renal biopsy specimens","volume":"83","author":"Jennette","year":"1985","journal-title":"Am J Clin Pathol"},{"key":"2024090510032153500_bib35","doi-asserted-by":"crossref","first-page":"370","DOI":"10.5935\/0101-2800.20170068","article-title":"Complement system and C4d expression in cases of membranous nephropathy","volume":"39","author":"Cust\u00f3dio","year":"2017","journal-title":"J Bras Nefrol"},{"key":"2024090510032153500_bib36","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.cca.2018.06.050","article-title":"Clinical and prognostic significance of glomerular C1q deposits in primary MN","volume":"485","author":"Zhang","year":"2018","journal-title":"Clin Chim Acta"},{"key":"2024090510032153500_bib37","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1038\/s41379-019-0267-z","article-title":"Diagnostic role of renal biopsy in PLA2R1-antibody-positive patients with nephrotic syndrome","volume":"32","author":"Wiech","year":"2019","journal-title":"Mod Pathol"},{"key":"2024090510032153500_bib38","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1007\/s00467-009-1439-8","article-title":"IgG subclasses and complement pathway in segmental and global membranous nephropathy","volume":"25","author":"Segawa","year":"2010","journal-title":"Pediatr Nephrol"},{"key":"2024090510032153500_bib39","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1681\/ASN.2012030242","article-title":"Antiphospholipase A2 receptor antibody titer and subclass in idiopathic membranous nephropathy","volume":"23","author":"Hofstra","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"2024090510032153500_bib40","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1681\/ASN.2017070805","article-title":"The most N-terminal region of THSD7A is the predominant target for autoimmunity in THSD7A-associated membranous nephropathy","volume":"29","author":"Seifert","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"2024090510032153500_bib41","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.3389\/fimmu.2018.03035","article-title":"Antigen-specific IgG subclasses in primary and malignancy-associated membranous nephropathy","volume":"9","author":"Von Haxthausen","year":"2018","journal-title":"Front Immunol"},{"key":"2024090510032153500_bib42","doi-asserted-by":"crossref","first-page":"1324804","DOI":"10.1155\/2019\/1324804","article-title":"Anti-PLA2R1 antibodies containing sera induce in vitro cytotoxicity mediated by complement activation","volume":"2019","author":"Lateb","year":"2019","journal-title":"J Immunol Res"},{"key":"2024090510032153500_bib43","first-page":"57","article-title":"Distribution of IgG subclasses in membranous nephropathy","volume":"58","author":"Doi","year":"1984","journal-title":"Clin Exp Immunol"},{"key":"2024090510032153500_bib44","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.ekir.2020.01.018","article-title":"Proteomic analysis of complement proteins in membranous nephropathy","volume":"5","author":"Ravindran","year":"2020","journal-title":"Kidney Int Rep"},{"key":"2024090510032153500_bib45","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1093\/ndt\/14.4.881","article-title":"Glomerular deposition of mannose-binding lectin in human glomerulonephritis","volume":"14","author":"Lhotta","year":"1999","journal-title":"Nephrol Dial Transplant"},{"key":"2024090510032153500_bib46","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1159\/000508665","article-title":"Effect of glomerular mannose-binding lectin deposition on the prognosis of idiopathic membranous nephropathy","volume":"45","author":"Zhang","year":"2020","journal-title":"Kidney Blood Press Res"},{"key":"2024090510032153500_bib47","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1093\/ndt\/gfx235","article-title":"Glomerular mannose-binding lectin deposition in intrinsic antigen-related membranous nephropathy","volume":"33","author":"Hayashi","year":"2018","journal-title":"Nephrol Dial Transplant"},{"key":"2024090510032153500_bib48","doi-asserted-by":"crossref","first-page":"e140453","DOI":"10.1172\/JCI140453","article-title":"Altered glycosylation of IgG4 promotes lectin complement pathway activation in anti-PLA2R1-associated membranous nephropathy","volume":"131","author":"Haddad","year":"2021","journal-title":"J Clin Invest"},{"key":"2024090510032153500_bib49","first-page":"1391","article-title":"C4d immunohistochemical staining is a sensitive method to confirm immunoreactant deposition in formalin-fixed paraffin-embedded tissue in membranous glomerulonephritis","volume":"26","author":"Val-Bernal","year":"2011","journal-title":"Histol Histopathol"},{"key":"2024090510032153500_bib50","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1056\/NEJMc1805857","article-title":"Factor H autoantibodies and membranous nephropathy","volume":"379","author":"Seikrit","year":"2018","journal-title":"N Engl J Med"},{"key":"2024090510032153500_bib51","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/s41467-023-36068-0","article-title":"The classical pathway triggers pathogenic complement activation in membranous nephropathy","volume":"14","author":"Seifert","year":"2023","journal-title":"Nat Commun"},{"key":"2024090510032153500_bib52","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/j.kint.2023.07.024","article-title":"Introduction of a novel chimeric active immunization mouse model of PLA2R1-associated membranous nephropathy","volume":"104","author":"Tomas","year":"2023","journal-title":"Kidney Int"},{"key":"2024090510032153500_bib53","doi-asserted-by":"crossref","first-page":"822508","DOI":"10.3389\/fimmu.2022.822508","article-title":"Strategies towards antigen-specific treatments for membranous nephropathy","volume":"13","author":"K\u00f6llner","year":"2022","journal-title":"Front Immunol"},{"key":"2024090510032153500_bib54","doi-asserted-by":"crossref","first-page":"15314","DOI":"10.1038\/ncomms15314","article-title":"Engineered clearing agents for the selective depletion of antigen-specific antibodies","volume":"8","author":"Devanaboyina","year":"2017","journal-title":"Nat Commun"},{"key":"2024090510032153500_bib55","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/j.kint.2024.01.021","article-title":"An antigen-specific chimeric autoantibody receptor (CAAR) NK cell strategy for the elimination of anti-PLA2R1 and anti-THSD7A antibody-secreting cells","volume":"105","author":"Seifert","year":"2024","journal-title":"Kidney Int"},{"key":"2024090510032153500_bib56","doi-asserted-by":"crossref","first-page":"1335998","DOI":"10.3389\/fimmu.2024.1335998","article-title":"Bi-specific autoantigen-T cell engagers as targeted immunotherapy for autoreactive B cell depletion in autoimmune diseases","volume":"15","author":"Perico","year":"2024","journal-title":"Front Immunol"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ckj\/advance-article-pdf\/doi\/10.1093\/ckj\/sfae243\/58813366\/sfae243.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/advance-article-pdf\/doi\/10.1093\/ckj\/sfae243\/59023145\/sfae243.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/advance-article-pdf\/doi\/10.1093\/ckj\/sfae243\/59023145\/sfae243.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T18:56:48Z","timestamp":1725562608000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ckj\/article\/doi\/10.1093\/ckj\/sfae243\/7733091"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,13]]},"references-count":56,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9,2]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfae243","relation":{},"ISSN":["2048-8505","2048-8513"],"issn-type":[{"value":"2048-8505","type":"print"},{"value":"2048-8513","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,9]]},"published":{"date-parts":[[2024,8,13]]},"article-number":"sfae243"}}